B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab
Juan Luis Chico‐García(Universidad de Alcalá), Luisa María Villar(Evidence (Italy)), Enric Monreal(Hospital Universitario Ramón y Cajal), Raquel Sainz-Amo(Instituto de Salud Carlos III), Fernando Rodríguez‐Jorge(Universidad de Alcalá), Lucienne Costa‐Frossard(Universidad de Alcalá), Ernesto Roldán(Hospital Universitario Ramón y Cajal), Jaime Masjuán(Universidad de Alcalá), Eulalia Rodríguez‐Martín(Instituto Ramón y Cajal de Investigación Sanitaria), Paulette Esperanza Walo-Delgado(Universidad de Alcalá)
Cited by 6
Related Papers
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
|New England Journal of Medicine|2019|823
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study
|European Journal of Neurology|2020|385